Florida Laboratory to Pay $9.8 Million to Resolve FCA Allegations Over Physician Compensation

Key Takeaways

• A Florida-based laboratory agreed to pay $9.8 million to resolve allegations under the False Claims Act (FCA) related to physician compensation arrangements that the government alleged violated the Stark Law.
• According to the Department of Justice (DOJ), the laboratory self-disclosed the compensation arrangements and cooperated with the government's investigation, factors that contributed to the resolution.
• The settlement underscores continued federal scrutiny of financial relationships between laboratories and referring physicians, reinforcing the importance of Stark Law and FCA compliance for clinical laboratories and pharmacy stakeholders involved in diagnostic testing.

A Florida laboratory has agreed to pay $9.8 million to resolve allegations that it violated the FCA by submitting claims to federal health care programs that stemmed from physician compensation arrangements prohibited under the federal physician self-referral law, commonly known as the Stark Law. The settlement resolves civil allegations only, and the laboratory admitted no liability as part of the agreement.

According to the DOJ, the matter arose after the laboratory voluntarily self-disclosed certain compensation arrangements involving referring physicians. Federal authorities alleged that these financial relationships did not satisfy applicable Stark Law exceptions, making resulting claims submitted to Medicare and other federal health care programs ineligible for reimbursement under the FCA.

Government Allegations

The DOJ alleged that the laboratory maintained compensation arrangements with physicians who referred patients for laboratory testing. Because the government contended those arrangements violated the Stark Law, any claims submitted to federal health care programs for services resulting from those referrals were alleged to be false under the FCA.

The settlement resolves these allegations without a determination of liability. As is customary in FCA settlements, the laboratory denied the allegations while agreeing to the monetary resolution.

Federal officials also emphasized that the laboratory voluntarily disclosed the conduct and cooperated throughout the investigation. According to the DOJ, that cooperation was considered during resolution of the matter.

Why This Matters for Pharmacy and Laboratory Compliance

Although the case centers on laboratory services rather than pharmacy dispensing, it highlights compliance issues that affect organizations participating in federally funded health care programs.

Clinical laboratories, pharmacies, physician practices, and other providers routinely maintain financial relationships involving testing, consulting, medical directorships, and other professional services. Federal regulators continue to examine whether these arrangements satisfy applicable Stark Law requirements when physicians refer designated health services reimbursed by Medicare or Medicaid.

For pharmacists working in integrated health systems, specialty pharmacy, and laboratory partnerships, the case reinforces the importance of ensuring that compensation arrangements are appropriately structured, commercially reasonable, and supported by applicable legal exceptions before claims are submitted to federal health care programs.

Compliance Takeaways

The DOJ's announcement highlights several practical compliance considerations for health care organizations:

• Review physician compensation arrangements for compliance with Stark Law requirements.
• Regularly evaluate consulting, medical director, and other professional service agreements involving referral sources.
• Maintain documentation demonstrating that compensation arrangements meet applicable legal exceptions.
• Promptly investigate potential compliance concerns and consider voluntary self-disclosure when appropriate.
• Recognize that cooperation with government investigations may be considered when resolving enforcement matters.

Bottom Line

The $9.8 million settlement illustrates the DOJ's continued enforcement of the FCA in cases involving physician financial relationships and laboratory testing. While the laboratory resolved the matter through a civil settlement following voluntary self-disclosure, the case serves as another reminder that compensation arrangements involving referral sources remain a significant compliance priority for laboratories and other health care organizations participating in federal health care programs.

Reference

Florida Laboratory Agrees to Pay $9.8M to Resolve False Claims Act Liability Relating to Self-Disclosure of Compensation Arrangements. US Department of Justice. Press release. Published July 20, 2026. Accessed July 21, 2026. https://www.justice.gov/opa/pr/telemedicine-company-owner-and-author-health-care-compliance-books-sentenced-136m-medicare